Magnetic resonance spectroscopy (MRS), also known as nuclear magnetic resonance (NMR) spectroscopy, is a non-invasive analytical technique that has been used to study metabolic changes in brain tumors, strokes, seizure disorders, Alzheimer's disease, depression and other diseases affecting the brain. It has also been used to study the metabolism of other organs.
Magnetic resonance spectroscopy can be done as part of a routine magnetic resonance imaging (MRI) on commercially available MRI instruments. The probe accessory necessary to perform MRS was granted 510(k) clearance from the Food and Drug Administration (FDA). Magnetic resonance spectroscopy and MRI use different software to acquire and mathematically manipulate the signal. Whereas MRI creates an image, MRS creates a graph or "spectrum" arraying the types and quantity of chemicals in the brain or other organs.
The role of MRS in diagnosis and therapeutic planning has not been established by adequate clinical studies. Specifically, there have been no clinical trials demonstrating improved outcomes in patients evaluated with MRS compared to patients evaluated with conventional imaging modalities.
The consensus in the literature is that further studies are necessary to determine MRS' role in the diagnosing and planning treatment in neurological diseases.
Magnetic resonance spectroscopy (MRS) in the evaluation of brain tumors (either primary tumors or brain metastases) is considered investigational/experimental because there is inadequate evidence in the published peer-reviewed clinical literature regarding its effectiveness.
An assessment of MRS prepared by the Tuft's-New England Medical Center Evidence-Based Practice Center for the Agency for Healthcare Research and Quality (AHRQ) (Jordan et al, 2003) reached the following conclusions: “[h]uman studies conducted on the use of MRS for brain tumors demonstrate that this non-invasive method is technically feasible and suggest potential benefits for some of the proposed indications. However, there is a paucity of high quality direct evidence demonstrating the impact on diagnostic thinking and therapeutic decision-making. In addition, the techniques of acquiring the MRS spectra and interpreting the results are not well standardized. In summary, while there are a large number of studies that confirm MRS' technical feasibility, there are very few published studies to evaluate its diagnostic accuracy and whether it can positively affect diagnostic thinking and therapeutic choice. Those studies that do address these areas often have significant design flaws including inadequate sample size, retrospective design and other limitations that could bias the results.”
A structured evidence review of MRS for evaluation of suspected brain tumor conducted by the BlueCross BlueShield Association Technology Evaluation Center (2003) concluded that “[t]he evidence is insufficient to permit conclusions concerning the effect of magnetic resonance spectroscopy on health outcomes.”
The Center for Medicare and Medicaid Services (CMS, 2004) has determined that there is insufficient evidence to deem MRS “reasonable and necessary” for brain tumor diagnosis. Due to “methodological shortcomings” in the 11 studies reviewed on the use of MRS for brain lesion detection and a lack of a controlled comparison of MRS and traditional diagnostic strategies, CMS has announced that it will continue its current national non-coverage determination.
Gluch (2005) stated that ex vivo and in vivo applications of MRS have been developed, which aid in distinguishing malignant from normal tissues. Studies of breast, colon, cervix, esophageal, and prostate cancer reveal both the successes and failings of present technology. The author noted that verification that these non-invasive tests might supplant conventional histology in obtaining spatial diagnostic and chemical prognostic information remains for the time being illusive.
Willmann et al (2006) evaluated the additional pre-operative value of (1)H MRS in identifying the epileptogenic zone (EZ) for epilepsy surgery by performing a meta-analysis. The authors concluded that MRS still remains a research tool with clinical potential. Their findings indicated the connection of ipsilateral MRS abnormality to good outcome. The ability for prediction of post-operative outcome may depend on the assessed population. They noted that prospective studies limited to non-localized ictal scalp electroencephalography or MRI-negative patients are needed for validation of these data. Furthermore, Hollingworth et al (2006) stated that (1)H MRS is a potentially useful adjunct to anatomical MRI in the characterization of brain tumors. These investigators performed an updated systematic review of the evidence. They concluded that the current evidence on the accuracy of (1)H MRS in the characterization of brain tumors is promising. However, additional high-quality studies are needed to convince policy makers.
The clinical evidence is not sufficient to permit conclusions on the health outcome effects of magnetic resonance spectroscopy in the evaluation of prostate cancer. Magnetic resonance spectroscopy (MRS) provides metabolic information about the prostate gland by assessing the prostatic metabolites choline and citrate. Alterations in levels of these metabolites may provide prognostic information that may be useful for treatment planning.
According to Jung and Westphalen (2012) studies have demonstrated that the addition of proton magnetic resonance spectroscopic imaging (1H-MRSI) to T2-weighted MR imaging improves tumor localization, volume estimation, staging, tissue characterization, and identification of recurrent disease after therapy. A recent multicenter study supported by the American College of Radiology Imaging Network, however, showed that the combination of 1H-MRSI and T2-weighted MR images does not improve tumor detection in patients with low-grade, low-volume disease selected to undergo radical prostatectomy. These results suggest that positive 1H-MRSI findings are more likely to reflect higher tumor grade and/or volume.
NCCN Clinical Practice Guidelines in Oncology for prostate cancer (2011) state: “A negative biopsy following post-radiation biochemical recurrence poses clinical uncertainties. Observation, androgen deprivation therapy (ADT), or enrolling in clinical trials are viable options. Alternatively, the patients may undergo more aggressive workup, such as repeat biopsy, MR spectroscopy, and/or endorectal MRI.”
According to the textbook Wein: Campbell-Walsh Urology (2011), in the initial evaluation of the patient with prostate cancer, tumor-selective imaging tests, such as monoclonal antibody scans, positron emission tomographic scans, magnetic resonance spectroscopy, and lymphotrophic magnetic resonsance imaging (MRI) are not widely used, although they might prove more useful in the future. The use of MRI, alone or in combination with MRS for tumor staging remains controversial. Current research involves the use of magnetic resonance spectroscopy to guide radiation administration by directing higher doses to the metabolically active areas of the tumor. Magnetic resonance spectroscopy–optimized implants are also under study to give higher doses to metabolically active regions of the tumor.
The textbook Abeloff’s Clinical Oncology (2008) states that new imaging technologies, including MRS give great potential for improving the assessment of local and distant prostate cancer extent.
In a retrospective trial, Fradet et al (2010) studied the role that MRI and MRS findings obtained at the time of diagnosis play in the progression of disease in patients whose prostate cancer is being managed with active surveillance and compared the role of these findings with the role of transrectal ultrasonography (US) findings. The final cohort included 114 patients with a median follow-up of 59 months. Two urologists blinded to the clinical outcome in these patients independently reviewed and dichotomized the MRI report and the MRS imaging report as normal or suggestive of malignancy. One urologist performed all US examinations that were then dichotomized similarly. Patients with a lesion that was suggestive of cancer at MRI had a greater risk of the Gleason score being upgraded at subsequent biopsy (hazard ratio, 4.0; 95% confidence interval: 1.1, 14.9) than did patients without such a lesion. Neither MRS imaging nor transrectal US could be used to predict cancer progression.
Westphalen and colleagues (2010), in a retrospective single-institution study, compared resonance (MR) spectroscopic imaging with T2-weighted MR imaging alone in the detection of locally recurrent prostate cancer after definitive external beam radiation therapy. Sixty-four men who underwent endorectal MR imaging, MR spectroscopic imaging, and transrectal ultrasonographically guided biopsy for suspected local recurrence of prostate cancer after definitive external beam radiation therapy were retrospectively identified. Thirty-three patients had also received androgen therapy. Recurrent cancer was determined to be present or absent in the left and right sides of the prostate at T2-weighted MR imaging and MR spectroscopic imaging by a radiologist and a spectroscopist, respectively. Area under the receiver operating characteristic curve (A(Z)) was calculated for T2-weighted MR imaging alone and combined T2-weighted MR imaging and MR spectroscopic imaging by using generalized estimating equations and by using biopsy results as the reference standard. Recurrent prostate cancer was identified at biopsy in 37 (58%) of the 64 men. Recurrence was unilateral in 28 patients and bilateral in nine (total of 46 affected prostate sides). A(Z) analysis revealed that use of combined T2-weighted MR imaging and MR spectroscopic imaging (A(Z) = 0.79), as compared with T2-weighted MR imaging alone (A(Z) = 0.67), significantly improved the detection of local recurrence (P = .001). The addition of MR spectroscopic imaging to T2-weighted MR imaging was found to significantly improve the diagnostic accuracy of endorectal MR imaging in the detection of locally recurrent prostate cancer after definitive external beam radiation therapy.
Zakian and colleagues (2005) evaluated whether hydrogen 1 MR spectroscopic imaging can be used to predict aggressiveness of prostate cancer. A total of 123 patients (median age, 58 years; age range, 40-74 years) who underwent endorectal MRI and MR spectroscopic imaging between January 2000 and December 2002 were included. MR imaging and spectroscopy were performed by using combined pelvic phased-array and endorectal probe. Data from 94 patients were included. Pathologic evaluation was used to identify 239 lesions. Overall sensitivity of MR spectroscopic imaging was 56% for tumor detection, increasing from 44% in lesions with Gleason score of 3 + 3 to 89% in lesions with Gleason score greater than or equal to 4 + 4. There was a trend toward increasing (Cho + Cr)/Cit with increasing Gleason score in lesions identified correctly with MR spectroscopic imaging. Tumor volume assessed with MR spectroscopic imaging increased with increasing Gleason score.
Kline, et al. (2006) measured citrate in samples from 61 participants, of whom 16 without and 21 with cancer donated semen, and 17 without and 7 with cancer donated expressed prostatic secretions. Mean citrate +/- SE compared to that in controls was 2.7-fold lower in patients with cancer samples in semen (132.2 +/- 30.1 vs 48.0 +/- 7.9 mM, p < 0.05) and expressed prostatic secretions (221.4 +/- 55.4 vs 81.5 +/- 36.0 mM, p < 0.05). ROC curve analysis showed that measurements of citrate in semen performed as well as measurements of citrate in expressed prostatic secretion for detecting prostate cancer (AUC 0.81, 95% CI 0.60 to 0.92 and AUC 0.73, 95% CI 0.38 to 0.90, respectively, p > 0.05). ROC curve analysis also showed that the measurement of citrate in either fluid outperformed prostate specific antigen measurement for detecting prostate cancer in these subjects (AUC 0.61, 95% CI 0.44 to 0.74). The authors concluded that in vitro nuclear MRS measurement of the citrate concentration in semen or expressed prostatic secretions outperforms prostate specific antigen testing for detecting prostate cancer.
Wetter, et al. (2006) examined fifty patients with biopsy-proven prostate carcinoma. For spectroscopy, a 3D chemical shift imaging (CSI) spin-echo sequence was used. Image interpretation was performed by two radiologists. The total number of tumor voxels and tumor voxels per slice were counted to estimate the tumor volume in every patient. The potential of MR spectroscopy to differentiate between T2 and T3 tumors, based on the estimated tumor volumes, was compared with the staging performance of MRI. The MR measurement time was 19.01 minutes, and the total procedure time averaged 35 minutes. Seventy-six percent of the spectroscopic examinations were successful. Statistically significant differences in the number of tumor voxels per slice and tumor volumes were found between T2 and T3 tumors. The descriptive parameters of MRI and MR spectroscopy did not differ significantly; sensitivity and specificity were 75% and 87%, respectively, for MRI and 88% and 70%, respectively, for MR spectroscopy. The combination of both methods resulted in only a slight improvement in staging performance and was not statistically significant. The authors concluded that combined MRI and MRS of the prostate has no diagnostic advantage in staging performance over MRI alone.
According to Shah et al. (2006), “although MRS has mainly been used in diagnostics and tumor evaluation for brain cancer, it is becoming an increasingly important adjunct to conventional diagnostic and monitoring procedures for cancer of the prostate, colon, breast, cervix, pancreas, and esophagus. The clinical usefulness of MRS has yet to be fully substantiated.”
Rajesh et al (2007) noted that 3D MRS is emerging as a new and sensitive tool in the metabolic evaluation of prostate cancer. Zapotoczna et al (2007) stated that the increasing sensitivity and specificity of MRS to the prostate is causing new interest in its potential role in the definition of target subvolumes at higher risk of failure following radical radiotherapy. Prostate MRS might also play a role as a non-invasive predictive factor for tumor response and treatment outcome. However, guidelnes on the pre-treatment staging of prostate cancer by the American College of Radiology (ACR)'s expert panel on urologic imaging and radiation oncology (Israel et al, 2007) stated that one group of investigators have demonstrated that prostate cancers have a characteristic loss of the citrate peak and gain in the choline/creatine peak on MRS imaging. Moreover, the ratio of choline to citrate is related to the Gleason score, suggesting that MRS imaging may provide information about tumor aggressiveness. Improvements in diagnostic accuracy and staging have been reported. However, MRS imaging is technically demanding and time consuming. It has not been proven in multi-institutional trials, although a clinical trial under the auspices of the American College of Radiology Imaging Network (ACRIN) is currently underway. Thus, MRS imaging can not yet be considered a routine diagnostic tool.
In a meta-analysis of the accuracy of prostate cancer studies which use MRS as a diagnostic tool, Wang et al (2008) concluded that as a new method in the diagnosis of prostate cancer, MRS has a better applied value compared to other common modalities. Ultimately, large scale randomized controlled trial studies are needed to evaluate its clinical value.
The clinical evidence is not sufficient to support the use of magnetic resonance spectroscopy in the evaluation of mucopolysaccharidosis. Vedolin and colleagues (2007) examined the influence of aging on conventional MRI and MRS findings of patients with mucopolysaccharidosis (MPS), and tested the correlation of enzyme levels, urinary glycosaminoglycans (GAG), and neuroimaging findings. A total of 60 patients with MPS types I (n = 8), II (n = 31), IV-A (n = 4), and VI (n = 17) underwent T2, fluid-attenuated inversion recovery (FLAIR), and MRS of the brain. For analysis of MRI variables, the researchers measured the normalized cerebral volume (NCV), CSF volume (NCSFV), ventricular volume (NVV), and lesion load (NLL) on FLAIR using semi-automated and automated segmentation techniques. For MRS, a point-resolved spectroscopy technique was used. Voxels were positioned at the white and gray matter. Statistical analysis involved Pearson or Spearman tests for correlation between neuroimaging, age, enzyme levels, and urinary GAG. The median age at onset of the disease was 20 months. Patients with longer disease duration had more NLL in the white matter (r = 0.28, p = 0.03), and this difference was more pronounced in MPS II patients (r = 0.44, p = 0.02). Metabolites ratios in MRS, NCV, NCSFV, and NVV did not correlate with disease duration or age of the patients (p > 0.05). Magnetic resonance imaging and MRS variables in either the white or the gray matter did not correlate with enzymatic activity or GAG levels. Patients with MPS II had a lower mean NCV (p < 0.001). The authors concluded that these findings showed that white matter lesion is more extensive as disease duration increases, especially in mucopolysaccharidosis type II patients. Magnetic resonance imaging and MRS findings did not correlate with either enzymatic or glycosaminoglycan levels.
Boesch et al (2007) evalauted and compared biochemical and volumetric features of the cerebellum in patients with spino-cerebellar ataxia type 2 (SCA2) and patients with the cerebellar variant of multiple system atrophy (MSA-C). Nine genetically assigned SCA2 patients and 6 MSA-C patients who met the clinical criteria of MSA-C underwent a clinical and neuro-radiological work-up with respect to cerebellar features. The MR protocol consisted of a sagittal T1-weighted 3-dimensional fast low-angle shot (3D FLASH) sequence and a transversal T2- and spin-density-weighted turbo spin-echo sequence. The proton magnetic resonance spectroscopic imaging ((1)H-MRSI) protocol consisted of 2 chemical shift imaging (CSI) sequences (echo time (TE) = 20 and 135 msec). Both short- and long-TE MRS images showed significant decreases in values for N-acetylaspartate to creatine (NAA/Cr), and choline to creatine (Cho/Cr) ratios in MSA-C and SCA2 compared to normal controls, though there was no difference between the 2 patient groups. In contrast, distinct cerebellar lactate (Lac) peaks were detected in 7 SCA2 patients, and small peaks were detected in 2. However, these investigators did not detect any definite Lac peak in MSA-C or control subjects. The authors concluded that MRSI revealed Lac pathology in SCA2 but not in MSA-C. Whether this indicates distinct pathogenetic mechanisms of cerebellar degeneration remains to be established.
Dyke et al (2007) explored (1)H MRSI as a means to assess peri-tumoral tissue response post-resection and Gliadel((R)) implantation in patients with high-grade gliomas. Pilot (1)H MRSI data are presented that demonstrate non-invasive, serial monitoring of metabolic changes at the tumor site following Gliadel implantation. Three patients with newly diagnosed glioblastoma multiforme (GBM) underwent MRI and (1)H MRSI at 3.0 Tesla prior to resection and at 3 to 5 and greater than or equal to 12 weeks post-operatively. Baseline MRS spectra of tumor tissue from all patients were characterized by marked increases of choline (CHO) and lactate (LAC), and a decrease of N-acetylaspartate (NAA), typical of GBM compared with normal contra-lateral brain tissue. Post-operatively, spectra were analyzed from the resection cavity and peri-tumoral regions and compared with normal tissue from the contra-lateral brain at baseline. In 2 of 3 patients, peri-tumoral NAA/CRE increased and CHO/NAA decreased compared to contra-lateral brain at 3 to 5 weeks compared with baseline following Gliadel therapy and surgery but prior to radiotherapy. This study indicated that (1)H MRSI has the ability to localize regions of heterogeneous response following Gliadel treatment. Although data are limited, these results suggested that metabolic indicators of outcome can be successfully monitored pre- and post-surgical resection and Gliadel implantation with (1)H MRSI. Additional study of patients receiving Gliadel Wafers using (1)H MRSI may serve to aid clinicians in assessing tumor regression and gauging efficacy of this chemotherapy treatment.
De Stefano et al (2007) reviewed current MRS clinical applications in multiple scloersis (MS), and discussed the potential and limitations of the technique, and suggested recommendations for the application of MRS to clinical trials. The authors concluded that despite some important limitations, proton MRS has the potential to be implemented in large, multi-centered clinical trials of MS. The usefulness of MRS-derived outcome measures in MS clinical trial has yet to be proven....Future studies and the few clinical trials that are currently incorporating MRS into their imaging protocols will reveal if MRS has a role in quantifying the impact of therapeutic intervention on tissue damage in MS and will help to determine if MRS can become a standard and accepted part of the assessment of MS treatment in the near future. European Federation of Neurological Societies guidelines on the use of neuroimaging in the management of MS (Filippi et al, 2006) noted that the performance and contribution of diffusion tensor MRI (DT-MRI) and MRS) in multi-center studies still have to be evaluated.
Biomarkers of disc degeneration have been previously described using NMR spectroscopy, but the link between discogenic back pain and biomarkers has not been completely understood. Keshari et al (2008) used quantitative ex vivo proton high resolution magic angle spinning (HR-MAS) NMR spectroscopy to identify biochemical markers associated with discogenic back pain. HR-MAS NMR spectroscopy was performed on snap frozen samples taken from 9 patients who underwent discectomies for painful disc degeneration. The resulting proton NMR spectrums were compared with those from discs harvested from a reference population consisting of 9 scoliosis patients. Spectral analyses demonstrated significantly lower proteoglycan (PG)/collagen (0.31 +/- 0.22 versus 0.77 +/- 0.48) and PG/lactate (0.46 +/- 0.24 versus 2.24 +/- 1.11) ratios, and a higher lactate/collagen (0.77 +/- 0.49 versus 0.40 +/- 0.21) ratio in specimens obtained from discogenic pain patients when compared with scoliosis patients. The authors concluded that these findings suggested that spectroscopic markers of proteoglycan, collagen, and lactate may serve as metabolic markers of discogenic back pain. These results provided a further basis of the potential to develop in vivo MRS for the investigation of discogenic back pain.
Guidelines on bone tumors by ACR's expert panel on musculoskeletal imaging (Morrison et al, 2005) noted that MRS has potential to differentiate benign from malignant lesions, however, more research is needed.
In a review on MRS as an imaging tool for cancer, Shah et al (2006) stated that the clinical usefulness of MRS has yet to be fully substantiated. As MRS availability and access increases, appropriate evaluations of its strengths and weaknesses will be made. The authors concluded that research to date and primary observation indicated that MRS is a promising clinical tool for oncologic management of patients.
Magnetic resonance spectroscopy in the evaluation of suspected breast cancer is considered experimental and investigational because there is inadequate evidence in the peer-reviewed clinical literature regarding its effectiveness.
Bartella and Huang (2007) stated that proton (hydrogen 1) [1H]) MRS provides biochemical information about the tissue under investigation. Its diagnostic value in cancer is typically based on the detection of elevated levels of choline compounds, choline being a marker of active tumor. The 2 main potential clinical applications of 1H MRS are (i) as an adjunct to breast MRI to improve specificity in differentiating benign from malignant lesions, and (ii) for monitoring or even predicting response to treatment in patients undergoing neoadjuvant chemotherapy. Preliminary data are promising, with study results suggesting that 1H MRS may decrease the number of benign biopsies recommended on the basis of MRI findings and may help predict response as early as 24 hours after the first dose of neoadjuvant chemotherapy. Although several limitations currently exist that make the technique premature for clinical use, further evaluation with larger, preferably multi-center trials is certainly warranted.
Tse et al (2007) noted that in vivo proton (1)H-MRS has been demonstrated to be successful in the differentiation of benign and malignant breast lesions in a non-invasive manner by detecting increased levels of composite choline (Cho) compounds. Currently there is molecular evidence of increased Cho metabolism in breast cancer cells. In breast malignancies, (1)H-MRS achieved a high-overall sensitivity (82 %). Most test cases were infiltrating duct carcinoma, but infiltrating lobular, medullary, mucinous and adenoid cystic carcinomas were also positive by (1)H-MRS. Large lesional size is a pre-requisite for (1)H-MRS testing, and technical problems account for some of the false negative results. Another potential of (1)H-MRS is to assess patients' response to neoadjuvant chemotherapy. In ductal carcinoma in situ, the results of (1)H-MRS on the limited number of cases were negative. Most of the assessed benign breast lesions including fibroadenoma, fibrocystic changes, cysts and galactoceles, papilloma, tubular adenoma and phyllodes tumors and were mostly negative by (1)H-MRS, with an overall false-positive rate was about 8 %. Normal breast tissue was almost always negative by (1)H-MRS, whereas, lactating breast tissue showed positivity with a slightly different spectrum on further analysis. With the clinical use of stronger field MR scanners and better coils, the sensitivity of (1)H-MRS may be further improved. With these improvements, (1)H-MRS may potentially be useful in detection of smaller malignant lesions, characterization of malignant lesions into non-invasive or invasive, and as an invaluable tool in disease progression monitoring.
Kesler et al (2009) stated that males with fragile X syndrome (FRAX) are at risk for significant cognitive and behavioral deficits, particularly those involving executive prefrontal systems. Disruption of the cholinergic system secondary to fragile X mental retardation protein deficiency may contribute to the cognitive-behavioral impairments associated with fragile X. These investigators measured choline in the dorso-lateral prefrontal cortex of 9 males with FRAX and 9 age-matched typically developing controls using (1)H MRS. Right choline/creatine was significantly reduced in the fragile X group compared to controls. In controls, both left and right choline was significantly positively correlated with intelligence and age was significantly negatively correlated with left choline. There were no correlations in the fragile X group. Subjects with FRAX participating in a pilot open-label trial of donepezil demonstrated significantly improved cognitive-behavioral function. The authors concluded that studies utilizing biochemical neuroimaging techniques such as these have the potential to significantly impact the design of treatment strategies for FRAX and other genetic disorders by helping identify neurochemical targets for intervention as well as serving as metrics for treatment efficacy.
Umbehr et al (2009) meta-analyzed the diagnostic accuracy of combined MRI/MRS in prostate cancer and explored risk profiles with highest benefit. The authors searched the MEDLINE and EMBASE databases and the Cochrane Library, and screened reference lists and contacted experts. There were no language restrictions. They identified 31 test-accuracy studies (1,765 patients); 16 studies (17 populations) with a total of 581 patients were suitable for meta-analysis. Nine combined MRI/MRS studies (10 populations) examining men with pathologically confirmed prostate cancer (297 patients; 1,518 specimens) had a pooled sensitivity and specificity on prostate subpart level of 68 % (95 % confidence interval [CI]: 56 to 78 %) and 85 % (95 % CI: 78 to 90 %), respectively. Compared with patients at high-risk for clinically relevant cancer (6 studies), sensitivity was lower in low-risk patients (4 studies) (58 % [46 to 69 %] versus 74 % [58 to 85 %]; p > 0.05) but higher for specificity (91 % [86 to 94 %] versus 78 % [70 to 84 %]; p < 0.01). Seven studies examining patients with suspected prostate cancer at combined MRI/MRS (284 patients) had an overall pooled sensitivity and specificity on patients level of 82 % (59 to 94 %) and 88 % (80 to 95%). In the low-risk group (5 studies), these values were 75 % (39 to 93 %) and 91 % (77 to 97 %), respectively. The authors concluded that a limited number of small studies suggested that MRI combined with MRS could be a rule-in test for low-risk patients. Moreover, they stated that these findings need further confirmation in larger studies and cost-effectiveness needs to be established.
In a prospective, multi-center study, Weinreb et al (2009) determined the incremental benefit of combined endorectal MRI and MRS, as compared with endorectal MRI alone, for sextant localization of peripheral zone (PZ) prostate cancer. A total of 134 patients with biopsy-proved prostate adenocarcinoma and scheduled to undergo radical prostatectomy were recruited at 7 institutions. T1-weighted, T2-weighted, and spectroscopic MR sequences were performed at 1.5 T by using a pelvic phased-array coil in combination with an endorectal coil. Eight readers independently rated the likelihood of the presence of PZ cancer in each sextant by using a 5-point scale -- first on MR images alone and later on combined MR-MRS images. Areas under the receiver operating characteristic curve (AUCs) were calculated with sextant as the unit of analysis. The presence or absence of cancer at centralized histopathologic evaluation of prostate specimens was the reference standard. Reader-specific receiver operating characteristic curves for values obtained with MRI alone and with combined MRI-MRS imaging were developed. The AUCs were estimated by using Mann-Whitney statistics and appropriate 95 % CI. Complete data were available for 110 patients (mean age of 58 years; range of 45 to 72 years). Magnetic resonance imaging alone and combined MRI-MRS imaging had similar accuracy in PZ cancer localization (AUC, 0.60 versus 0.58, respectively; p > 0.05). AUCs for individual readers were 0.57 to 0.63 for MRI alone and 0.54 to 0.61 for combined MRI-MRS imaging. The authors concluded that in patients who undergo radical prostatectomy, the accuracy of combined 1.5-T endorectal MRI-MRS imaging for sextant localization of PZ prostate cancer is equal to that of MRI alone.
In a phase I study, Lee et al (2009) examined the use of SR4554, a fluorine-containing 2-nitroimidazole, as a hypoxia marker detectable with 19F MRS. These researchers investigated higher doses of SR4554 and intra-tumoral localization of the 19F MRS signal. Patients who had tumors greater than or equal to 3 cm in diameter and less than or equal to 4 cm deep were included in this study. Measurements were performed using 1H/19F surface coils and localized 19F MRS acquisition. SR4554 was administered at 1,400 mg m(-2), with subsequent increase to 2,600 mg m(-2) using prophylactic metoclopramide. Spectra were obtained immediately post-infusion (MRS no. 1), at 16 hrs (MRS no. 2) and 20 hrs (MRS no. 3), based on the SR4554 half-life of 3.5 hrs determined from a previous study. 19Fluorine retention index (%) was defined as (MRS no. 2/MRS no. 1)*100. A total of 26 patients enrolled at: 1,400 (n = 16), 1,800 (n = 1), 2,200 (n = 1) and 2,600 mg m(-2) (n = 8). SR4554 was well-tolerated and toxicities were all less than or equal to grade 1; mean plasma elimination half-life was 3.7 +/- 0.9 hrs. SR4554 signal was seen on both unlocalized and localized MRS no. 1 in all patients. Localized 19F signals were detected at MRS no. 2 in 5 out of 9 patients and 4 out of 5 patients at MRS no. 3. The mean retention index in tumor was 13.6 (range of 0.6 to 43.7) compared with 4.1 (range of 0.6 to 7.3) for plasma samples taken at the same times (p = 0.001) suggesting (19)F retention in tumor and, therefore, the presence of hypoxia. The authors concluded that they have demonstrated the feasibility of using 19F MRS with SR4554 as a potential method of detecting hypoxia. Certain patients showed evidence of 19F retention in tumor, supporting further development of this technique for detection of tumor hypoxia.
Sturrock et al (2010) evaluated in vivo brain metabolite differences in control subjects, individuals with pre-manifest Huntington disease (pre-HD), and individuals with early HD using ¹H MRS and assessed their relationship with motor performance. A total of 85 subjects (30 controls, 25 pre-HD, and 30 early HD) were recruited as part of the TRACK-HD study; 84 were scanned at 3 T with single-voxel spectroscopy in the left putamen. Disease burden score was greater than 220 among pre-HD individuals. Subjects underwent TRACK-HD motor assessment including Unified Huntington's Disease Rating Scale (UHDRS) motor scoring and a novel quantitative motor battery. Statistical analyses included linear regression and 1-way analysis of variance. Total N-acetylaspartate (tNAA), a neuronal integrity marker, was lower in early HD (about 15 %) versus controls (p < 0.001). N-acetylaspartate (NAA), a constituent of tNAA, was lower in pre-HD (about 8 %) and early HD (about 17 %) versus controls (p < 0.05). The glial cell marker, myo-inositol (mI), was 50 % higher in early HD versus pre-HD (p < 0.01). In early HD, mI correlated with UHDRS motor score (R² = 0.23, p < 0.05). Across pre-HD and early HD, tNAA correlated with performance on a tongue pressure task (R² = 0.30, p < 0.0001) and with disease burden score (R² = 0.17, p < 0.005). This study demonstrated lower putaminal tNAA in early HD compared to controls in a cross-section of subjects. A novel biomarker role for mI in early HD was also identified. These findings resolve disagreement in the literature about the role of MRS as an HD biomarker. The authors concluded that putaminal MRS measurements of NAA and mI are promising potential biomarkers of HD onset and progression. Moreover, they stated that the longitudinal assessment of their cohort, and replication of this study in a second large pre-manifest and early HD cohort, ideally in the setting of a therapeutic trial, will be necessary to fully validate these findings.
Beadle and Frenneaux (2010) noted that 31-phosphorous ((31)P) MRS is a technique that allows the non-invasive characterization of the biochemical and metabolic state of the myocardium in vivo. Magnetic resonance spectroscopy is a pure form of molecular imaging using magnetic resonance signals from nuclei with nuclear spin to assess cardiac metabolism without the need for external radioactive tracers. (31)P MRS provides information on the underlying metabolic abnormalities that are fundamental to common conditions including ischemic heart disease, cardiomyopathy, hypertrophy and valvular disease. (31)P MRS could potentially also have a role to play in assessing response to therapy as well as the effectiveness of metabolic modulating agents. However, the use of MRS is currently limited to research due to its poor reproducibility, low spatial and temporal resolution, and long acquisition times. With technical advances in both the spectrometers and post-processing, MRS is likely to play a role in the future of multi-modal non-invasive cardiac assessment.
Horska and Barker (2010) noted that the utility of MRS in diagnosis and evaluation of treatment response to human brain tumors has been widely documented. These researchers discussed the role of MRS in tumor classification, tumors versus non-neoplastic lesions, prediction of survival, treatment planning, monitoring of therapy, and post-therapy evaluation. They concluded that there is a need for standardization and further study in order for MRS to become widely used as a routine clinical tool.
The clinical evidence is not sufficient to permit conclusions on the health outcome effects of magnetic resonance spectroscopy in the evaluation of leukoencephalopathy. In a 2008 article, Bizzi ,et al. report that childhood white matter disorders often show similar MR imaging signal-intensity changes, despite different underlying pathophysiologies. The purpose of this study was to determine if proton MR spectroscopic imaging ((1)H-MRSI) may help identify tissue pathophysiology in patients with leukoencephalopathies. Seventy patients (mean age, 6; range, 0.66-17 years) were prospectively examined by (1)H-MRSI; a diagnosis of leukoencephalopathy due to known genetic defects leading to lack of formation, breakdown of myelin, or loss of white matter tissue attenuation (rarefaction) was made in 47 patients. The diagnosis remained undefined (UL) in 23 patients. Patients with definite diagnoses were assigned (on the basis of known pathophysiology) to 3 groups corresponding to hypomyelination, white matter rarefaction, and demyelination. Choline (Cho), creatine (Cr), and N-acetylaspartate (NAA) signals from 6 white matter regions and their intra- and intervoxel (relative to gray matter) ratios were measured. Analysis of variance was performed by diagnosis and by pathophysiology group. Stepwise linear discriminant analysis was performed to construct a model to predict pathophysiology on the basis of (1)H-MRSI, and was applied to the UL group. Analysis of variance by diagnosis showed 3 main metabolic patterns. Analysis of variance by pathophysiology showed significant differences for Cho/NAA (P < .001), Cho/Cr (P < .004), and NAA/Cr (P < .002). Accuracy of the linear discriminant analysis model was 75%, with Cho/Cr and NAA/Cr being the best parameters for classification. On the basis of the linear discriminant analysis model, 61% of the subjects in the UL group were classified as hypomyelinating.